### Learner Notification

**Society of Gynecologic Oncology**

**2022 Palliative Care Series Part #1**

**Enduring: September 15, 2022 - September 15, 2023**

**Online**

**Acknowledgement of Financial Commercial Support**

AstraZeneca

**Acknowledgement of In-Kind Commercial Support**

No in-kind commercial support was received for this educational activity.

**Joint Accreditation Statement**

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Society of Gynecologic Oncology (SGO). Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Physicians (ACCME) Credit Designation**

Amedco LLC designates this **enduring material** for a maximum of **2.50** *AMA PRA Category 1 Credits*TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses (ANCC) Credit Designation**

Amedco LLC designates this activity for a maximum of **2.50** ANCC contact hours.

**Pharmacists and Pharmacy Technicians (ACPE) Credit Designation**

Amedco LLC designates this activity for a maximum of **2.50** knowledge-based CPE contact hours.

**NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.**

###### Objectives - After Attending This Program You Should Be Able To

1. Manage and treat cancer related side effects, including anxiety/depression, fatigue, nausea/vomiting malignant bowel obstruction.
2. Discuss palliative care's approach to improve the quality of life of patients and their families.
3. Establish palliative care for patients to manage symptoms in the last 24-48 hours of life.

**Disclosure of Conflict of Interest**

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-­‐6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

|  |  |  |  |
| --- | --- | --- | --- |
| **First** | **Last** | **Role** | **Commercial Interest** |
| Maria | Bell | Speaker | NA |
| Lindsay | Brubaker | Speaker, Planning Committee | NA |
| Diana | English | Speaker | NA |
| Ellen | Hartenbach | Speaker, Co-Author | NA |
| Katherine | Hicks-Courant | Speaker | NA |
| Carolyn | Lefkowis | Speaker, Planner | NA |
| Tracy | Sandstrom | CE Coordinator | NA |
| Lori | Spoozak | Reviewer, Chair, Planning Committee | NA |